Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tilray Brands operates as a diversified cannabis and consumer packaged goods company with operations across medical/recreational cannabis in Canada, Europe, and select US markets (hemp/CBD), plus craft beverage alcohol brands (SweetWater Brewing, Montauk Brewing) acquired in 2021. The company faces structural headwinds from Canadian cannabis oversupply, regulatory delays in US federal legalization, and European medical market fragmentation, while burning significant cash with negative operating margins exceeding -275%. Stock trades at 0.7x sales reflecting deep skepticism about path to profitability and dilution risk from $160M debt load on $800M market cap.
Tilray operates cultivation facilities in Canada (Nanaimo, Enniskillen) and Portugal (Cantanhede) producing cannabis at estimated $0.75-$1.25/gram all-in costs, selling into wholesale and retail channels. Canadian recreational margins compressed by provincial pricing pressure and black market competition (legal market ~$4.5B vs $3B illicit). European medical operates on import/distribution model with 20-30% gross margins but fragmented reimbursement. Beverage alcohol provides stable 40-50% gross margins but limited scale (~$250M annual revenue). Company lacks pricing power in commoditized Canadian flower market, faces regulatory barriers to US THC entry, and burns cash on SG&A exceeding $300M annually supporting multi-country infrastructure.
US federal cannabis legislation progress (SAFE Banking Act, rescheduling from Schedule I to III, state-level legalization momentum) - any positive regulatory news drives 20-40% single-day moves
Canadian cannabis market pricing trends and provincial wholesale rate changes - further price compression accelerates cash burn
European medical cannabis reimbursement expansion (Germany's April 2024 partial legalization implementation, UK NHS coverage decisions)
Equity dilution risk and liquidity events - company has raised capital via ATM offerings multiple times, diluting shareholders by 30%+ since 2021
M&A speculation or beverage alcohol segment performance - craft beer provides non-cannabis revenue diversification narrative
US federal legalization timeline uncertainty - company's valuation embedded 2024-2025 legalization hopes now pushed to 2027+ under current political gridlock, limiting addressable market to $4.5B Canada vs $30B+ potential US market
Canadian cannabis oversupply structural imbalance - 800+ licensed cultivators for $4.5B market creates permanent margin pressure, with black market retaining 35-40% share due to price/convenience advantages
European medical fragmentation - 27 different regulatory regimes, inconsistent reimbursement, and domestic cultivation preferences (Germany's April 2024 rules favor local production) limit scalability
Commoditization of THC products - flower pricing declined 60% since 2020 legalization, with limited brand differentiation as consumers prioritize price over quality in mature markets
Canadian market share erosion to Canopy Growth, Aurora Cannabis, and 800+ smaller licensed producers in race-to-bottom pricing environment
US MSO competitive advantages if federal legalization occurs - Curaleaf, Trulieve, Green Thumb already control state-licensed retail/cultivation infrastructure, creating 3-5 year head start vs Canadian entrants
Beverage alcohol craft segment consolidation - AB InBev, Molson Coors acquiring craft brands with superior distribution scale, while hard seltzer trend peaked in 2021 pressuring SweetWater positioning
Cash burn of $100M+ annually with $200M liquidity provides 18-24 month runway before dilutive capital raise required - historical pattern of 20-30% shareholder dilution per financing event
Goodwill and intangible assets of $400M+ (estimated 50% of assets) face impairment risk if cannabis valuations remain depressed - SweetWater acquisition premium at risk
Negative tangible book value and ROE of -114% indicate value destruction - company trading at 0.4x book reflects market skepticism of asset recovery
Debt covenant risks if EBITDA targets missed - limited disclosure on maintenance covenants but typical cannabis credit agreements include liquidity and EBITDA/interest coverage tests
moderate - Cannabis demonstrates recession-resistant characteristics (addiction/habitual use patterns), but discretionary recreational spending vulnerable in downturns. Craft beverage alcohol highly cyclical, with premium beer/spirits purchases declining 15-25% in recessions. European medical cannabis less cyclical due to reimbursement, but consumer sentiment affects Canadian recreational volumes. Current negative margins mean any revenue decline accelerates cash burn crisis.
High sensitivity through multiple channels: (1) $160M debt load faces refinancing risk if rates remain elevated - current 0.20 debt/equity understates risk given negative equity, (2) cannabis sector valuation multiples compress significantly in high-rate environment as speculative growth stocks lose appeal vs fixed income, (3) consumer financing costs affect discretionary cannabis/alcohol spending, (4) potential US market entrants face higher capital costs delaying competitive entry. Rising rates from current levels would pressure already-distressed valuation.
Moderate - Company's ability to refinance $160M debt dependent on credit market conditions and cannabis sector sentiment. Limited access to traditional banking (federal illegality) forces reliance on alternative lenders at higher spreads. Tightening credit conditions could force dilutive equity raises. Consumer credit conditions affect discretionary cannabis spending but less than traditional retail.
Speculative growth/momentum - Stock attracts retail investors betting on US federal legalization catalyst and institutional short-sellers targeting cash burn/dilution. High short interest (typically 15-25% of float) creates volatility around regulatory news. Not suitable for value investors given negative earnings and uncertain path to profitability, nor dividend investors (no dividend, negative FCF). Options traders active around legislative events and earnings due to 80-120% implied volatility.
high - Historical beta above 2.0, with 50-100% annualized volatility driven by regulatory headline risk, sector rotation, and liquidity concerns. Single-day moves of 15-30% common around US legislative votes or Canadian market data releases. Stock declined 27% in past 3 months, 34% in 6 months reflecting sector-wide derating as legalization timeline extends.
